Introduction
============

Abnormally high cancer cell growth is the basis for cancer development and progression. Inhibiting tumor cell growth and division is therefore fundamental in the development of cancer therapies ([@b1-ol-0-0-10111]). Pancreatic cancer is a malignancy that develops from the pancreas and is responsible for \>200,000 cases of mortality worldwide every year ([@b2-ol-0-0-10111]). Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. Treatment outcomes for PDAC are generally poor due to the existence of distant tumor metastasis in 80--90% of patients at the time of diagnosis, since metastasis is a contraindication for surgical resection ([@b3-ol-0-0-10111]). Therefore, early tumor detection is crucial.

Transforming growth factor β (TGF-β) signaling exerts dual functions in cancer biology ([@b4-ol-0-0-10111]). For example, TGF-β signaling stimulates tumor metastasis through epithelial-mesenchymal transition (EMT) in the late stages of various types of cancer ([@b5-ol-0-0-10111]). However, TGF-β signaling activation in early stages of tumor growth inhibits tumor cell proliferation in most types of cancer, including PDAC ([@b5-ol-0-0-10111],[@b6-ol-0-0-10111]). Therefore, TGF-β signaling pathway inhibition is considered a promising therapeutic target in pancreatic cancer ([@b6-ol-0-0-10111]). The crosstalk between TGF-β signaling and long non-coding RNAs (lncRNAs) has been reported in previous studies ([@b7-ol-0-0-10111],[@b8-ol-0-0-10111]). Notably, long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) presents tumor suppressive potential in various types of cancer ([@b9-ol-0-0-10111],[@b10-ol-0-0-10111]). A previous study reported that Linc-pint is decreased in plasma and tumor tissues of patients with pancreatic cancer, and that Linc-pint expression can distinguish patients with pancreatic cancer from healthy controls ([@b9-ol-0-0-10111]); however, the role of Linc-pint in pancreatic cancer development and progression remains unclear. Although Linc-pint is downregulated in numerous types of cancer, its roles and underlying molecular mechanisms of action in cancer biology remain unknown ([@b10-ol-0-0-10111]). In addition, Garitano-Trojaola *et al* ([@b11-ol-0-0-10111]) reported that Linc-pint is downregulated in acute lymphoblastic leukemia and participates in leukemic cell abnormal proliferation. Results from the present study suggested that Linc-pint may serve as a potential upstream activator of TGF-β signaling in PDAC.

Materials and methods
=====================

### Subject enrollment and plasma preparation

A total of 206 patients with PDAC were diagnosed and treated at the West China Hospital (Chengdu, China) between January 2014 and January 2018. Among these patients, 46 were selected to serve as a patient group according to strict inclusion and exclusion criteria. The inclusion criteria were as follows: i) Patients diagnosed and treated for the first time, ii) patients diagnosed with PDAC through pathological examinations, iii) patients with stage 0--1 PDAC \[according to the American Joint Committee on Cancer (AJCC) ([@b12-ol-0-0-10111])\] and iv) patients willing to participate. The exclusion criteria were as follows: i) Patients with other severe diseases, ii) patients who were treated prior to admission, iii) patients with chronic diseases, iv) patients with mental disorders and v) patients \>70 years old. The patient group comprised 29 men and 17 women who were aged between 21 and 68 years (mean age, 45.5±6.1 years). Whole blood (10 ml) was extracted in the morning of the day following admission. Simultaneously, blood samples from 36 healthy volunteers who received routine physiological examination at the West China Hospital were collected and served as a control group. The control group included 23 men and 13 women who were aged between 23 and 66 years (mean age, 46.1±6.0 years). No significant differences in age and sex were found between the two groups. Blood samples were centrifuged in EDTA-containing tubes for 12 min at 1,200 × g and room temperature. Supernatants were collected as the plasma samples and stored in liquid nitrogen prior to use. The present study was approved by the Ethics Committee of West China Hospital. All subjects provided written informed consent.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from plasma samples or cells with TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). For TGF-β1 treatment, cells were treated by exogenous TGF-β1 (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) dissolved in medium to 1, 10, 20 and 50 ng/ml for 24 h prior to RNA extraction. SuperScript III Reverse Transcriptase system (Thermo Fisher Scientific, Inc.) was used to synthesize cDNA according to the following conditions: 55°C for 40 min and 75°C for 15 min. RT-qPCR reactions were performed using SYBR^®^ Green Real-Time PCR Master Mixes (Thermo Fisher Scientific, Inc.) as follows: 1 min at 95°C, followed by 40 cycles at 95°C for 20 sec and 45 sec at 58°C. The following primers were used in PCR reactions: Linc-pint, forward 5′-CGTGGGAGCCCCTTTAAGTT-3′, reverse 5′-GGGAGGTGGCGTAGTTTCTC-3′; and β-actin, forward 5′-GACCTCTATGCCAACACAGT-3′ and reverse 5′-AGTACTTGCGCTCAGGAGGA-3′. The relative expression levels of Linc-pint were normalized to the endogenous control β-actin and were analyzed using the 2^−ΔΔCq^ method ([@b13-ol-0-0-10111]).

### TGF-β1 detection by ELISA

TGF-β1 plasma levels were measured using a human TGF-β1 ELISA kit (cat. no. RAB0460; Sigma-Aldrich; Merck KGaA) according to the manufacturer\'s protocol.

### Cell lines, cell culture and cell transfection

The human PDAC PL45 \[cat. no. American Type Culture Collection (ATCC)^®^ CRL-2558™\] and normal human pancreatic ductal hTERT-HPNE (cat. no. ATCC^®^ CRL-4023™) cell lines were purchased from ATCC (Manassas, VA, USA). Cells were cultured in ATCC-formulated Dulbecco\'s modified Eagle\'s medium (cat. no. 30-2002; ATCC) containing 10% fetal bovine serum (Sangon Biotech Co., Ltd., Shanghai, China) at 37°C in a humidified incubator containing 5% CO~2~.

PCR amplification was performed using Linc-pint primer with *Nhe*I cutting site at the 5′end to obtain full-length Linc-pint cDNA using Pfu DNA Polymerase kit (Promega Corporation, Madison, WI, USA). PCR product was subjected to agarose gel purification and was inserted into a linearized *Nhe*I-pEGFPC3 vector (Clontech Laboratories, Inc., Mountainview, CA, USA) to produce the Linc-pint expression vector. Cells from both cell lines were cultured for 8--12 h to reach 80--90% confluence. Cells (5×10^5^) were then transfected with 10 nM vectors using Lipofectamine^®^ 2000 reagent (cat. no. 11668-019; Invitrogen; Thermo Fisher Scientific, Inc.). Untransfected cells represented the control group. Cells transfected with empty vectors represented the negative control (NC) group. Experiments were performed 24 h following transfection.

### Cell proliferation assay

Linc-pint expression was detected by RT-qPCR 24 h post-transfection. Cell Counting Kit-8 (CCK-8; Sigma-Aldrich; Merck KGaA) was used to detect cell proliferation when the Linc-pint overexpression rate reached \>200% compared with control cells. A 5×10^4^ cells/ml cell suspension was prepared and a 100-µl cell suspension containing 5×10^3^ cells was seeded into a 96-well plate. For TGF-β1 treatment, cells were treated with exogenous TGF-β1 for 24 h at 37°C, prior to seeding into the 96-well plate. For TGF-β inhibitor treatment, cells were treated with 10 ng/ml SD 208, which is a potent ATP-competitive TGF-β receptor inhibitor (R&D Systems, Inc., Minneapolis, MN, USA) for 24 h at 37°C, prior to seeding into the 96-well plate. The plate was placed in the incubator, and CCK-8 solution (10 µl) was added after 12, 24, 48, 72 and 96 h for 4 h at 37°C. Optical density was measured at 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### Western blotting

Cells were lysed using radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, Inc.) and the protein concentration was measured using a bicinchoninic acid assay kit according to the manufacturers\' protocol. Proteins (20 µg) were separated by 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. The membranes were blocked in 5% skimmed milk for 1 h at room temperature and incubated with rabbit primary antibodies against TGF-β1 (cat. no. ab92486; 1:1,500; Abcam, Cambridge, MA, USA) and GAPDH (cat. no. ab9485; 1:1,000; Abcam) overnight at 4°C. Membranes were then incubated with horseradish peroxidase-conjugated immunoglobulin G secondary antibody (cat. no. MBS674747; 1:1,000; MyBioSource, Inc., San Diego, CA, USA) for 2.5 h at room temperature. Signals were detected using enhanced chemiluminescence reagent (Sigma-Aldrich; Merck KGaA). Data were analyzed via densitometry using ImageJ software v1.6 (National Institutes of Health, Bethesda, MD, USA).

### Statistical analysis

Statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Gene expression and cell proliferation data were expressed as the means ± standard deviation. Data comparisons were performed by Student\'s t-test (comparison between two groups) or one-way analysis of variance followed by least-significant difference test (comparison between multiple groups). The association between Linc-pint plasma levels and the clinical characteristics of patients with PDAC was analyzed by χ^2^ test. Pearson correlation coefficient was used for correlation analysis. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to assess the diagnostic value of plasma Linc-pint in patients with PDAC. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Plasma levels of Linc-pint and TGF-β1 are significantly lower in patients with early stage PDAC

Plasma levels of Linc-pint and TGF-β1 in patients with PDAC and healthy controls were measured by RT-qPCR and ELISA, respectively. As presented in [Fig. 1](#f1-ol-0-0-10111){ref-type="fig"}, significantly lower plasma levels of Linc-pint ([Fig. 1A](#f1-ol-0-0-10111){ref-type="fig"}) and TGF-β1 ([Fig. 1B](#f1-ol-0-0-10111){ref-type="fig"}) were detected in patients with PDAC compared with in healthy controls (P\<0.05).

### Downregulation of Linc-pint plasma levels distinguishes patients with PDAC from healthy controls

ROC analysis was performed to evaluate the diagnostic value of plasma Linc-pint in patients with PDAC. As presented in [Fig. 2](#f2-ol-0-0-10111){ref-type="fig"}, AUC was 0.8934, with a standard error of 0.03646 and 95% confidence interval of 0.8219--0.9649 (P\<0.001). AUC \>0.65 indicated potential diagnostic values.

### Plasma levels of Linc-pint and TGF-β1 are positively correlated in patients with PDAC but not in healthy controls

Pearson correlation coefficient was used to assess the correlation between plasma Linc-pint and TGF-β1 levels. As presented in [Fig. 3A](#f3-ol-0-0-10111){ref-type="fig"}, Linc-pint and TGF-β1 plasma levels were positively correlated in patients with PDAC (P\<0.0001). Conversely, no correlation between plasma levels of Linc-pint and TGF-β1 was detected in healthy controls (P=0.1289).

### Plasma levels of Linc-pint are significantly associated with tumor size in patients with PDAC

Patients with PDAC were divided into high (n=23) and low (n=23) expression groups according to the median plasma level of Linc-pint. The association between Linc-pint plasma levels and clinical characteristics of patients with PDAC was analyzed by χ^2^ test. As presented in [Table I](#tI-ol-0-0-10111){ref-type="table"}, plasma levels of Linc-pint were significantly associated with tumor size (P\<0.01), but not with age, sex, and drinking and smoking habits (P\>0.05).

### Linc-pint overexpression upregulates TGF-β1 in PDAC cells

Cells overexpressing Linc-pint were generated to further investigate the interactions between Linc-pint and TGF-β1. As presented in [Fig. 4A](#f4-ol-0-0-10111){ref-type="fig"}, Linc-pint overexpression was reached in PL45 and hTERT-HPNE cell lines compared with control and NC cells. In addition, PL45 cells overexpressing Linc-pint exhibited significantly upregulated TGF-β1 expression (P\<0.05). However, Linc-pint overexpression had no significant effects on TGF-β1 in hTERT-HPNE cells (P\>0.05). Conversely, treatment with exogenous TGF-β1 at 1, 10, 20 and 50 ng/ml for 24 h had no significant effects on Linc-pint expression in both cell lines ([Fig. 4B](#f4-ol-0-0-10111){ref-type="fig"}).

### Linc-pint overexpression and treatment with exogenous TGF-β1 inhibit PDAC cell proliferation

CCK-8 assay was performed to detect cell proliferation under different conditions. Linc-pint overexpression or treatment with exogenous TGF-β1 significantly inhibited PL45 cell proliferation compared with control and NC cells (P\<0.05; [Fig. 5A](#f5-ol-0-0-10111){ref-type="fig"}). In addition, treatment with SD 208 at 10 ng/ml significantly increased PDAC cell proliferation and reduced the inhibitory effects of Linc-pint overexpression and exogenous TGF-β1 treatment on cell proliferation (P\<0.05; [Fig. 5A](#f5-ol-0-0-10111){ref-type="fig"}). However, none of the aforementioned treatments had significant effect on hTERT-HPNE cell proliferation (P\>0.05; [Fig. 5B](#f5-ol-0-0-10111){ref-type="fig"}).

Discussion
==========

Although Linc-pint has been described as a tumor suppressor in various types of cancer, the underlying mechanisms of action of Linc-pint are mainly based on *in vitro* cell experiments, whereas clinical findings are lacking. The present study demonstrated that Linc-pint may be a tumor suppressive lncRNA in PDAC and may possess diagnostic value. In addition, results suggested that Linc-pint action may be associated with TGF-β1 upregulation.

In most types of cancer, TGF-β signaling activation inhibits tumor cell growth at early stages of tumor development but promotes tumor metastasis at late stages ([@b14-ol-0-0-10111]). A previous study reported that TGF-β signaling has a tumor suppressive role during pancreatic cancer initiation ([@b15-ol-0-0-10111]). To further confirm the role of TGF-β in pancreatic cancer, the present study only included patients with PDAC at AJCC stage 0 and 1, where the tumor had not spread to nearby lymph nodes or distant sites. Results demonstrated that TGF-β1 plasma levels were significantly downregulated in patients with PDAC compared with in healthy controls. In addition, treatment with exogenous TGF-β1 inhibited PDAC cell proliferation. These findings suggested that TGF-β signaling may have a tumor suppressive role during PDAC initiation.

Linc-pint downregulation has been reported in various types of human cancer cell lines ([@b10-ol-0-0-10111]). A recent study reported that Linc-pint is downregulated in plasma and tumor tissues of patients with pancreatic cancer, of which 80% have PDAC ([@b9-ol-0-0-10111]). Similarly, results from the present study demonstrated that Linc-pint plasma levels were decreased in patients with PDAC compared with in healthy controls, which suggested that Linc-pint may act as a tumor suppressor in PDAC. In addition, TGF-β signaling can interact with lncRNAs to participate in physiological and pathological processes ([@b7-ol-0-0-10111],[@b8-ol-0-0-10111]). For example, certain lncRNAs, including plasmacytoma variant translocation 1, promote EMT through TGF-β signaling to accelerate tumor metastasis in pancreatic cancer ([@b16-ol-0-0-10111]). However, the association between lncRNAs and TGF-β signaling in human PDAC growth remains unknown. In the present study, a positive correlation between Linc-pint and TGF-β1 plasma levels was observed in patients with PDAC. In addition, Linc-pint overexpression promoted TGF-β1 expression in PDAC cells, but treatment with TGF-β1 failed to affect Linc-pint expression. Furthermore, treatment with a TGF-β inhibitor reduced the inhibitory effects of Linc-pint overexpression on PDAC cell proliferation. These results suggested that Linc-pint may be an upstream activator of TGF-β1, which could inhibit PDAC growth. However, since there was no correlation between Linc-pint and TGF-β1 plasma levels in healthy controls, and because Linc-pint overexpression had no effect on TGF-β1 expression in normal pancreatic ductal cells, the regulatory effects of Linc-pint on TGF-β1 expression may be mediated by other disease factors.

A recent study reported that Linc-pint downregulation has diagnostic and prognostic values in patients with pancreatic cancer at different pathological stages ([@b9-ol-0-0-10111]). Conversely, the present study investigated the role of Linc-pint in tumor growth in early stages PDAC, and revealed the molecular mechanism underlying Linc-pint involvement in PDAC. Results from the present study demonstrated that Linc-pint plasma level were not associated with age, sex, and smoking and drinking habits, although these characteristics were reported to affect the expression of certain lncRNAs ([@b17-ol-0-0-10111]--[@b21-ol-0-0-10111]). These findings suggested that Linc-pint may serve as a reliable diagnostic marker for patients with early stage PDAC.

A potential limitation of the present study is that Linc-pint function was not investigated in an animal model of PDAC. However, *in vivo* experiments will be performed in future investigations to further confirm the findings from the present study. In addition, TGF-β has been reported to be a key regulator in proliferation of multiple, but not all types, of cells ([@b22-ol-0-0-10111]). In the present study, the hTERT-HPNE cell line exhibited no significant difference in cell proliferation following treatment with increasing doses of TGF-β1, which suggested that TGF-β signaling may not be a regulator of hTERT-HPNE cells.

In conclusion, Linc-pint and TGF-β1 were downregulated in early stage PDAC, and this study suggested that Linc-pint may inhibit PDAC growth by activating the TGF-β pathway.
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![Linc-pint and TGF-β1 plasma levels are significantly lower in patients with early stage PDAC. Comparison of plasma levels of Linc-pint (reverse transcription-quantitative polymerase chain reaction) and TGF-β1 (ELISA) between two groups revealed significantly lower plasma levels of (A) Linc-pint and (B) TGF-β1 in patients with PDAC compared with in healthy controls. Experiments were performed in triplicate. \*P\<0.05. Linc-pint, long intergenic non-protein coding RNA, p53 induced transcript; PDAC, pancreatic ductal adenocarcinoma; TGF-β1, transforming growth factor β1.](ol-17-05-4633-g00){#f1-ol-0-0-10111}

![ROC analysis of the diagnostic value of Linc-pint plasma levels in PDAC. ROC curve analysis was performed to evaluate the diagnostic value of plasma Linc-pint for PDAC. Results revealed that downregulation of Linc-pint plasma levels distinguished patients with PDAC from healthy controls. Linc-pint, long intergenic non-protein coding RNA, p53 induced transcript; PDAC, pancreatic ductal adenocarcinoma; ROC, receiver operating curve.](ol-17-05-4633-g01){#f2-ol-0-0-10111}

![Linc-pint and TGF-β1 plasma levels are positively correlated in (A) patients with pancreatic ductal adenocarcinoma but not in (B) healthy controls (Pearson correlation coefficient). Linc-pint, long intergenic non-protein coding RNA, p53 induced transcript; TGF-β1, transforming growth factor β1.](ol-17-05-4633-g02){#f3-ol-0-0-10111}

![Linc-pint overexpression upregulates TGF-β1 in PDAC cells. (A) Western blotting revealed that Linc-pint overexpression upregulated TGF-β1 in PDAC cells but not in normal pancreatic ductal cells. (B) Reverse transcription-quantitative polymerase chain reaction demonstrated that treatment with exogenous TGF-β1 had no significant effect on Linc-pint expression levels in both cell lines. Experiments were performed three times. \*P\<0.05. C, control; Linc-pint, long intergenic non-protein coding RNA, p53 induced transcript; NC, negative control; PDAC, pancreatic ductal adenocarcinoma; TGF-β1, transforming growth factor β1.](ol-17-05-4633-g03){#f4-ol-0-0-10111}

![PL45 and hTERT-HPNE cell proliferation under various conditions. (A) Cell Counting Kit-8 assay demonstrated that Linc-pint overexpression and treatment with exogenous TGF-β1 significantly inhibited cancer cell proliferation. Treatment with SD 208 significantly increased pancreatic ductal adenocarcinoma cell proliferation and decreased the inhibitory effects of Linc-pint overexpression and exogenous TGF-β1 treatment on cell proliferation. (B) No significant differences in the hTERT-HPNE cell proliferation were observed after similar treatments. This experiment was performed three times. \*P\<0.05. C, control; Linc-pint, long intergenic non-protein coding RNA, p53 induced transcript; NC, negative control; SD 208, potent ATP-competitive TGF-βRI inhibitor; TGF-β1, transforming growth factor β1.](ol-17-05-4633-g04){#f5-ol-0-0-10111}

###### 

Association between long intergenic non-protein coding RNA, p53 induced transcript plasma levels and clinicopathological characteristics of patients with pancreatic ductal adenocarcinoma.

  Variable                      Cases   High-expression   Low-expression   χ^2^   P-value
  ----------------------------- ------- ----------------- ---------------- ------ ---------
  Age (years)                                                                     0.37
    ≥45                         25      11                14               0.79   
    \<45                        21      12                  9                     
  Sex                                                                             0.13
    Male                        29      12                17               2.33   
    Female                      17      11                  6                     
  Primary tumor diameter (cm)                                                     \<0.01
    ≥2                          28        9               19               9.12   
    \<2                         18      14                  4                     
  Smoking                                                                         0.38
    Yes                         23      10                13               0.78   
    No                          23      13                10                      
  Drinking                                                                        0.35
    Yes                         31      14                17               0.89   
    No                          15        9                 6                     
